Larotrectinib, LARODX, Larotrectinib, 25mg

Manufacturer: Laos Daxiong Pharmaceutical

Description: 25mg*60 capsules

Larotrectinib is a potent, oral, selective tropomyosin receptor kinase (TRKs) inhibitor designed to directly target TRK (including TRKB, TRKB, and TRKC), shutting down the signaling pathway that leads to the growth of TRK fusion tumors.

Larotrectinib is a "cancer-free" therapy. It is the world's first oral TRK inhibitor designed specifically for patients with NTRK gene fusion cancer. NTRK gene fusion can be found in a variety of solid tumor types, including pancreatic cancer, thyroid cancer, salivary gland cancer, breast cancer, colorectal cancer, lung cancer, etc., especially in some rare cancers such as infantile fibrosarcoma, breast secretory carcinoma-like, breast secretory carcinoma, the incidence of NTRK gene fusion can reach more than 90%. Therefore, TRK inhibitors have broad-spectrum anti-tumor activity.